DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Ovarian Choriocarcinoma — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian Choriocarcinoma maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ovarian choriocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
BRCA2 DNA repair associated (BRCA2) — BRCA2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet atpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8PBC · 2.61 Å · ligand ADENOSINE-5'-TRIPHOSPHATE (ATP). Experimental structure, not a prediction.
What the evidence adds up to
A 2003 case report used DNA microsatellite analysis to show that an ovarian choriocarcinoma forming a large mass 40 days after the patient’s last menstrual period contained one maternal and two paternal alleles at several independent loci. The authors concluded this was the first description of an ovarian pregnancy of a partial hydatidiform mole giving rise to ovarian choriocarcinoma.
A 2023 case report described a postmenopausal woman with abnormal vaginal bleeding and an abdominal mass. She had been menopausal for more than eight years, her last abortion was nine years earlier, and she had an elevated serum β-hCG. After exploratory laparotomy, histopathology and immunohistochemistry led to a diagnosis of primary nongestational ovarian choriocarcinoma. She received cytoreductive surgery plus adjuvant chemotherapy with bleomycin, etoposide, and cisplatin. Serum β-hCG fell to normal after two cycles, and there was no evidence of recurrence after four cycles. The authors noted that nongestational ovarian choriocarcinoma is rare, aggressive, has limited sensitivity to chemotherapy, and carries a very poor prognosis.
A 2024 report emphasised that gestational and non-gestational ovarian choriocarcinoma require different treatment approaches, and that molecular-genetic testing to detect paternal genetic material in the tumour can reliably determine the tumour’s origin. The report presented a clinical case to illustrate this point.
No abstract provides survival rates, response rates beyond a single patient, or sample sizes larger than one. The 2023 case is the only one reporting a treatment outcome, and it is a single patient with no recurrence after four cycles. What is still missing are prospective trials, any randomised or controlled data, standardised treatment protocols, and patient stratification by genetic origin of the tumour.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Obstetrics and Gynecology · 2003 · 14 citations
Ovarian choriocarcinoma arising from partial mole as evidenced by deoxyribonucleic acid microsatellite analysis
AbstractBACKGROUND: Recent developments in genetic analysis allow determination of the origin of choriocarcinoma (ie, gestational or nongestational), which helps determine the strategy for clinical treatment of the disease. CASE: We present a case of ovarian choriocarcinoma forming a huge ovarian mass 40 days after the patient's last menstrual period. Deoxyribonucleic acid microsatellite analysis of the tumor revealed that it contained a single maternal and two paternal alleles at several independent loci, consistent with the tumor resulting from ovarian pregnancy of a partial hydatidiform mole. CONCLUSION: This is the first description of an ovarian pregnancy of a partial hydatidiform mole-derived ovarian choriocarcinoma.
World Journal of Clinical Cases · 2023 · 2 citations · open access
Primary ovarian choriocarcinoma occurring in a postmenopausal woman: A case report
AbstractBACKGROUND: Nongestational ovarian choriocarcinoma (NGOC) is a rare but aggressive neoplasm with limited sensitivity to chemotherapy and a very poor prognosis. Few cases of NGOC have been reported, and there is limited information regarding its clinical features, treatment protocols, or prognosis. CASE SUMMARY: decade of life visited our clinic because of abnormal vaginal bleeding and an abdominal mass. Although she had been menopausal for more than eight years and her last abortion occurred nine years ago, she had an increased level of serum β-human chorionic gonadotropin (β-hCG). Thus, an ovarian neoplasm of trophoblastic origin was suspected, and exploratory laparotomy was performed. Based on the patient's clinical history and the histopathological examination and immunohistochemistry results obtained postoperatively, we concluded that she most likely had primary NGOC. Cytoreductive surgery was performed in combination with adjuvant chemotherapy comprising bleomycin, etoposide, and cisplatin. Serum β-hCG levels decreased to normal after two cycles, and there was no evidence of recurrence after four cycles of chemotherapy. CONCLUSION: Even in postmenopausal women, ovarian choriocarcinoma should be considered in the initial differential diagnosis for an adnexal mass.
Malignant tumours · 2024 · 0 citations · open access
Choriocarcinoma of the ovaries: the role of molecular-genetic testing in the differential diagnosis of gestational and non-gestational forms
AbstractThe treatment approach for gestational and non-gestational ovarian choriocarcinoma has several differences, and their differential diagnosis requires special attention. The implementation of molecular-genetic testing which determines the presence of paternal genetic material in the tumor allows for a reliable determination of the origin of ovarian choriocarcinoma. The presented clinical case demonstrates the importance of this method in the differential diagnosis of gestational and non-gestational forms of ovarian choriocarcinoma.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
